Studies open for recruitment
1. Protocol: 747-303 (PI: Dr Mark McCullen)
Short Title: The REGENERATE Study.
Protocol Title: A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatitis.
2. Protocol: 3152-301-002 (PI: Dr Darrell Crawford)
Short Title: The AURORA Study.
Protocol Title: A Phase 3 Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects With Nonalcoholic Steatohepatitis
3. Protocol: LJ401-HH01 (PI: Dr Darrell Crawford)
Protocol Title: A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study with LJPC-401 for the Treatment of Iron Overload in Adult Patients with Hereditary Hemochromatosis
4. Protocol: 747-304 (PI: Dr Mark McCullen)
Short Title: The REVERSE Study.
Protocol Title: A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
1. Protocol: MK-3475-022. KEYNOTE-022 (PI: Dr Victoria Atkinson)
Short Title: The KEYNOTE-022 study
Lay Title: A study to investigate MK-3475 (pembrolizamab) in combination with trametinib and dabrafenib in patients with advanced melanoma.
2. Protocol: Protocol: CA224-020 (PART D) (PI: Dr Victoria Atkinson)
Lay Title: An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid (Part D: melanoma that HAVE previously been treated with immunotherapy)
3. Protocol: CK-101-101 (PI: Dr Ken O’Byrne)
Lay Title: Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors
4. Protocol: INCAGN 1876-201 (PI: Dr Warren Joubert)
Lay Title: A Clinical trial with the purpose to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies in subjects with advanced or metastatic malignancies.
5. Protocol: 2125-MEL-301(PI: Dr Victoria Atkinson)
Short Title: The ILLUMINATE 301 study
Protocol Title: A Randomized Phase 3 Comparison of IMO-2125 with Ipilimumab versus Ipilimumab Alone in Subjects with Anti-PD-1 Refractory Melanoma
Lay Title: A Phase 3 comparison of ipilimumab with and without IMO-2125 in advanced melanoma
6. Protocol: CA224-047 (PI: Dr Victoria Atkinson)
Protocol Title: A Randomized, Double-Blind Phase 2/3 Study of Relatlimab Combined with Nivolumab versus Nivolumab in Participants with Previously Untreated Metastatic or Unresectable Melanoma
Lay Title: A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma
7. Protocol: I8X-MC-JECA (Part B & C) (PI: Dr Victoria Atkinson)
Lay Title: A Phase 1 Study of LY3200882 in Patients with Solid Tumors
8. Protocol: (D081SC00001) (PI: Dr Pretoria Bilinski)
Short Title: The PROpel study
Protocol Title: A Randomised, Double-blind, Placebo-controlled, Multicentre Phase III Study of Olaparib Plus Abiraterone Relative to Placebo Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (PROpel Study)
9. Protocol: (MK3475-495) (PI: Dr Ken O’Byrne)
Short Title: KEYNOTE-495; KeyImPaCT
Protocol Title: A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab-(MK-3475, SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (KEYNOTE-495; KeyImPaCT)
Lay Title: A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495)
1. Protocol: INS1007-201 (PI: Dr Rachel Thomson)
Short Title: The WILLOW Study
Protocol Title: Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Assess the Efficacy, Safety & Tolerability, and PK of INS1007 Administered Once Daily for 24 Weeks in Subjects With Non-CF Bronchiectasis
2. Protocol: Z7224L01 (PI: Dr Rachel Thomson)
Short Title: The PROMIS I Study
Protocol Title: A Double-blind, Placebo-controlled, Multi-centre, Clinical Trial to Investigate the Efficacy and Safety of 12 Months of Therapy With Inhaled Colistimethate Sodium in the Treatment of Subjects With Non-cystic Fibrosis Bronchiectasis Chronically Infected With Pseudomonas Aeruginosa (P. Aeruginosa)
Lay Title: Long Term Efficacy and Safety of Inhaled Colistimethate Sodium in Bronchiectasis Subjects With Chronic Pseudomonas Aeruginosa Infection. (PROMIS-I)